LCK酪氨酸激酶与mTOR信号通路在T细胞急性淋巴细胞白血病中的治疗靶向研究
研究利用斑马鱼T-ALL体外高通量筛选平台鉴定能杀伤白血病细胞的药物组合,发现AKT/mTORC1抑制剂与广谱酪氨酸激酶抑制剂达沙替尼具有强协同作用,该组合可杀伤部分复发及地塞米松耐药斑马鱼T-ALL,并在人T-ALL细胞系、原代细胞及小鼠PDX中有效抑制白血病生长且耐受良好。机制上达沙替尼抑制LCK磷酸化及TCR信号,联合mTORC1抑制通过降低MCL-1蛋白诱导T-ALL细胞死亡。
要点
- AKT/mTORC1抑制剂与达沙替尼联合在斑马鱼T-ALL中显示强协同杀伤作用。
- 该组合可杀伤部分复发及地塞米松耐药的斑马鱼T-ALL。
- 联合治疗在人T-ALL细胞系、原代细胞及小鼠PDX中有效且耐受良好。
核心结论
- LCK激酶及其调控的下游TCR信号在抑制凋亡和驱动白血病持续生长中具有此前未认识的作用。
- 对大量原代人T-ALL及小鼠PDX的分析提示,替西罗莫司联合达沙替尼治疗可能对大部分人类T-ALL有效。
研究设计与样本
- 研究采用体外高通量筛选平台鉴定可杀伤斑马鱼T-ALL的药物组合,并在人类疾病中进行临床前验证。
- 验证体系包括人T-ALL细胞系、原代人T-ALL及小鼠体内生长的患者来源异种移植瘤(PDX)。
主要发现
- AKT/mTORC1抑制剂与广谱酪氨酸激酶抑制剂达沙替尼之间发现强药物协同作用。
- 相同药物组合可有效杀伤部分复发及地塞米松耐药的斑马鱼T-ALL。
- 该组合在人T-ALL细胞系和原代人T-ALL中有效抑制T-ALL生长,在小鼠PDX中耐受良好并有效抑制白血病生长。
- 机制上达沙替尼抑制淋巴细胞特异性蛋白酪氨酸激酶(LCK)的磷酸化与激活,削弱T细胞受体(TCR)信号通路,与mTORC1抑制联合时通过降低MCL-1蛋白表达诱导强效T-ALL细胞杀伤。
临床怎么用
- 目前正在其他儿童肿瘤适应症中开展mTORC1抑制剂替西罗莫司联合达沙替尼的临床试验,据此将该疗法优先用于临床前测试。
- 作者分析提示替西罗莫司联合达沙替尼治疗可能对大部分人类T-ALL有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse and refractory T-cell acute lymphoblastic leukemia (T-ALL) has a poor prognosis, and new combination therapies are sorely needed. Here, we used an ex vivo high-throughput screening platform to identify drug combinations that kill zebrafish T-ALL and then validated top drug combinations for preclinical efficacy in human disease. This work uncovered potent drug synergies between AKT/mTORC1 (mammalian target of rapamycin complex 1) inhibitors and the general tyrosine kinase inhibitor dasatinib. Importantly, these same drug combinations effectively killed a subset of relapse and dexamethasone-resistant zebrafish T-ALL. Clinical trials are currently underway using the combination of mTORC1 inhibitor temsirolimus and dasatinib in other pediatric cancer indications, leading us to prioritize this therapy for preclinical testing. This combination effectively curbed T-ALL growth in human cell lines and primary human T-ALL and was well tolerated and effective in suppressing leukemia growth in patient-derived xenografts (PDX) grown in mice. Mechanistically, dasatinib inhibited phosphorylation and activation of the lymphocyte-specific protein tyrosine kinase (LCK) to blunt the T-cell receptor (TCR) signaling pathway, and when complexed with mTORC1 inhibition, induced potent T-ALL cell killing through reducing MCL-1 protein expression. In total, our work uncovered unexpected roles for the LCK kinase and its regulation of downstream TCR signaling in suppressing apoptosis and driving continued leukemia growth. Analysis of a wide array of primary human T-ALLs and PDXs grown in mice suggest that combination of temsirolimus and dasatinib treatment will be efficacious for a large fraction of human T-ALLs.
引用
- Laukkanen S, Veloso A, Yan C, et al. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood. 2022. PMID: 35544598. doi:10.1182/blood.2021015106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。